COMMUNIQUÉS West-GlobeNewswire

Evaxion Regains Compliance with Nasdaq Minimum Bid Price Requirement
07/02/2024
COPENHAGEN, Denmark, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today [...]
Terns Pharmaceuticals Appoints Amy Burroughs as Chief Executive Officer
07/02/2024
Proven Industry Executive Brings More Than 25 Years of Leadership Experience FOSTER CITY, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage [...]
MatrixCare Earns Three 2024 Best in KLAS Awards
07/02/2024
MatrixCare has been named a market leader by KLAS Research for its Home Health EHR in three Categories: Home Health – Independent – Large, Home Health – Independent – Small, and Hospice – Independent BLOOMINGTON, Minn [...]
ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at the 2024 BIO CEO & Investor Conference to Provide Corporate Update and Discuss Key Milestones
07/02/2024
ZyVersa is advancing a dynamic pipeline of drug candidates with multiple programs built around two proprietary technologies – Cholesterol Efflux Mediator™ VAR 200 for treatment of kidney diseases, and Inflammasome ASC [...]
Nextech Named 2024 Best in KLAS: Ambulatory Specialty EHR
07/02/2024
TAMPA, Fla., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Nextech, a leading provider of clinical and administrative healthcare technology solutions for specialty physician practices, today announced its EHR software is a top- [...]
Jasper Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Conference
07/02/2024
REDWOOD CITY, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) [...]
BriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case
07/02/2024
Disease control rate of 61% observed in evaluable Phase 2 patients treated with the same formulation in BriaCell’s pivotal Phase 3 study Disease control rate of 50% in evaluable patients treated with the Phase 3 [...]
FundaMental Pharma GmbH announces publication of a groundbreaking Proof-of-Concept Study in Cell Reports Medicine using a TwinF Interface Inhibitor for the Treatment of Amyotrophic Lateral Sclerosis
07/02/2024
PRESS RELEASE FundaMental Pharma GmbH announces publication of a groundbreaking Proof-of-Concept Study in Cell Reports Medicine using a TwinF Interface Inhibitor for the Treatment of Amyotrophic Lateral Sclerosis [...]
Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
07/02/2024
SAN DIEGO, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases [...]
Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
07/02/2024
CAMBRIDGE, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host virtual 1x1 investor [...]
Renexxion Ireland’s European Partner, Dr. Falk Pharma GmbH, has Elected PPI-non-responsive Symptomatic GERD as the Second Naronapride Indication to Develop and Commercialize in their Licensed Territories
07/02/2024
ROSCREA, Ireland, and FREIBURG, Germany, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company committed to delivering innovative drugs to patients with high [...]
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™
07/02/2024
New data show additional improvement and stabilization in clinical outcomes in MPS II with 104 weeks of tividenofusp alfa (DNL310) treatment in the open-label, single-arm Phase 1/2 study; sustained normalization of CSF [...]
Recce Pharmaceuticals Establishes Strategic Partnership in South-East Asia to Accelerate Clinical Program
07/02/2024
Memorandum of Understanding (MoU) with leading Indonesian biomedical company PT Etana Biotechnologies MoU aims to facilitate late-stage clinical trials in Indonesia, supporting the Indonesian Government’s access to [...]
Artios Pharma Strengthens Financial Leadership with Appointment of Christine Silverstein as Chief Financial Officer
07/02/2024
CAMBRIDGE, United Kingdom and NEW YORK, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Artios Pharma Limited (“Artios”), clinical-stage biotech company led by pioneers of DNA damage response (“DDR”) drug development, announces the [...]
Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
07/02/2024
SEATTLE, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule protein analysis platform, today announced it will report financial results [...]
Clearside Biomedical Announces Pricing of $15 Million Registered Direct Offering
07/02/2024
ALPHARETTA, Ga., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (“Clearside” or the “Company”) (NASDAQ: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye [...]
PetVivo Holdings, Inc. Announces Release of Clinical Study Results Involving Feline Tolerance to Intra-articular Injections of Spryng™ with OsteoCushion™ Technolgoy
07/02/2024
MINNEAPOLIS, MN, US, Feb. 07, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the “Company” or “PetVivo") an emerging biomedical device company focused on the commercialization of innovative [...]
Disc Medicine Strengthens Leadership Team with Appointment of Seasoned Industry Executive Jean Franchi as Chief Financial Officer, and Promotion of Jonathan Yu to Chief Operating Officer
07/02/2024
Jean Franchi is an industry veteran and brings over 30 years of leadership experience in finance, investor relations, capital formation, and operations at both development and commercial-stage companies Jonathan Yu, [...]
Stryker declares a $0.80 per share quarterly dividend
07/02/2024
Portage, Michigan, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.80 per share payable April 30, 2024 to shareholders of record at the [...]

Pages